Factor Bioscience Inc., a biotechnology company based in Cambridge, Massachusetts, has recently added three new members to its translational science team. The team will be led by Kyle Garland, Ph.D., who joins Factor as the Director of Translational Science. Dr. Garland, along with Associate Scientists Raven Hinkel and Elizabeth Belcher, bring deep expertise in mRNA and cell engineering to Factor.
Dr. Matt Angel, Co-Founder, Chairman, and CEO of Factor, expressed excitement about the new additions to the team. He believes that Dr. Garland and his team’s experience in synthetic mRNA, mRNA cell reprogramming, gene editing, cell manufacturing, immunoengineering, and nucleic acid formulation will enhance Factor’s ability to support strategic partners and accelerate the translation of technologies into new products.
Dr. Garland is optimistic about Factor’s extensive portfolio of foundational mRNA and cell-engineering technologies. He believes that these technologies have the potential to revolutionize biotechnology research and development. Dr. Garland previously led the Department of Research and Development at Eterna Therapeutics, overseeing preclinical programs and strategic collaborations.
With a Doctor of Philosophy degree in Chemical Engineering from Vanderbilt University and a Bachelor of Science degree in Bioengineering from Lehigh University, Dr. Garland brings a wealth of expertise to Factor Bioscience. The company focuses on developing technologies that engineer cells to promote health and improve lives
